Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Division of Nephrology, University of Alabama, Birmingham, Alabama, USA.
Nephrology (Carlton). 2021 Apr;26(4):303-311. doi: 10.1111/nep.13857. Epub 2021 Feb 23.
Obesity and intensive systolic blood pressure (SBP) control are independently associated with greater risk of acute kidney injury (AKI) and incident chronic kidney disease (CKD). We examined whether baseline body mass index (BMI) modifies the effects of intensive SBP lowering on AKI or incident CKD.
The systolic blood pressure intervention trial (SPRINT) randomized 9361 participants with high blood pressure to an SBP target of either <120 mm Hg or < 140 mm Hg. In a secondary analysis of 9210 SPRINT participants with a baseline BMI of ≥18.5 and < 50 kg/m , we examined the interactions of baseline BMI and SPRINT SBP intervention on subsequent AKI and incident CKD.
Each 5 kg/m increase in baseline BMI was associated with higher risk of AKI (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.01 to 1.25) and incident CKD (HR 1.17, 95% CI 1.01 to 1.32). Intensive SBP control increased the risk of AKI (HR 1.68, 95% CI 1.22-2.11) and incident CKD (HR 3.49, 95% CI 2.47-4.94). The increased risk of AKI with intensive SBP control was consistent across the baseline BMI spectrum (linear interaction p = 0.55); however, the risk of incident CKD with SPRINT intervention increased with higher BMI (linear interaction p = 0.043).
The increased risk of adverse kidney events seen with intensive SBP control in the SPRINT persisted across the baseline BMI spectrum. A higher baseline BMI was associated with an augmented risk of incident CKD with intensive SBP control.
肥胖和强化收缩压(SBP)控制与急性肾损伤(AKI)和新发慢性肾脏病(CKD)的风险增加独立相关。我们研究了基线体重指数(BMI)是否会改变强化 SBP 降低对 AKI 或新发 CKD 的影响。
收缩压干预试验(SPRINT)将 9361 名高血压患者随机分为 SBP 目标值<120mmHg 或<140mmHg。在 SPRINT 的 9210 名基线 BMI≥18.5 和<50kg/m 的参与者的二次分析中,我们研究了基线 BMI 和 SPRINT SBP 干预对随后 AKI 和新发 CKD 的交互作用。
基线 BMI 每增加 5kg/m,AKI 的风险就会增加(风险比 [HR] 1.12,95%置信区间 [CI] 1.01 至 1.25)和新发 CKD(HR 1.17,95% CI 1.01 至 1.32)。强化 SBP 控制增加了 AKI 的风险(HR 1.68,95% CI 1.22-2.11)和新发 CKD(HR 3.49,95% CI 2.47-4.94)。强化 SBP 控制增加 AKI 的风险在整个基线 BMI 范围内是一致的(线性交互作用 p=0.55);然而,SPRINT 干预后新发 CKD 的风险随着 BMI 的升高而增加(线性交互作用 p=0.043)。
SPRINT 中强化 SBP 控制导致的不良肾脏事件风险增加在整个基线 BMI 范围内持续存在。较高的基线 BMI 与强化 SBP 控制后新发 CKD 的风险增加相关。